Wexford Capital’s Atara Biotherapeutics ATRA Stock Holding History

Wexford Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,198	Closed	-$15.4K	–	214
2023 Q4	$15.4K	Buy	+1,198	New	+$27.9K	﹤0.01%	211

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wexford Capital's ATRA Position: Q1 2024 in Review

Wexford Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 1,198 shares — an estimated $15.4K sold.

Wexford Capital first reported a position in ATRA in Q4 2023 and held it in 1 quarter. The position peaked at $15.4K in Q4 2023. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

Wexford Capital reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 1,198 Atara Biotherapeutics shares in Q1 2024, an estimated $15.4K.
Wexford Capital first reported a position in Atara Biotherapeutics in Q4 2023 and held it in 1 quarter.
Wexford Capital's Atara Biotherapeutics position peaked at $15.4K in Q4 2023.
82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.